Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. It also has a collaboration agreement with Sinopharm A-Think Pharmaceuticals Co., Ltd. for the development, manufacture, and commercialization of Zoptrex, which has completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer in the People's Republic of China. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone843-900-3223
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$920,000.00
Profitability
Miscellaneous
Employees34
Next Earnings Date3/27/2019 (Estimated)
OptionableOptionable
AEterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions
What is AEterna Zentaris' stock symbol?
AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."
How were AEterna Zentaris' earnings last quarter?
AEterna Zentaris Inc. (NASDAQ:AEZS) posted its earnings results on Tuesday, November, 6th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.10. The biopharmaceutical company had revenue of $0.66 million for the quarter. AEterna Zentaris had a return on equity of 83.33% and a net margin of 34.40%. View AEterna Zentaris' Earnings History.
When is AEterna Zentaris' next earnings date?
What price target have analysts set for AEZS?
2 equities research analysts have issued 1 year price objectives for AEterna Zentaris' stock. Their predictions range from $2.00 to $3.00. On average, they anticipate AEterna Zentaris' share price to reach $2.50 in the next year. This suggests that the stock has a possible downside of 39.5%. View Analyst Price Targets for AEterna Zentaris.
What is the consensus analysts' recommendation for AEterna Zentaris?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AEterna Zentaris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AEterna Zentaris.
What are Wall Street analysts saying about AEterna Zentaris stock?
Here are some recent quotes from research analysts about AEterna Zentaris stock:
- 1. HC Wainwright analysts commented, "We maintain our Buy rating of AEZS and raise our 12-month price target to $5.50 per share, up from $3.00. We derive our price target using a risk-adjusted net present value analysis of potential US and EU royalties, discounted at 18%, to reach a total rNPV of $66M for the royalty streams. To this we add net cash of $17M, less long-term liabilities of $15M, and add expected European license payment of $55M, to reach an enterprise value of $132M. Based on this analysis, we derive a price target of $5.72 per diluted share, which we round to $5.50." (1/17/2019)
- 2. According to Zacks Investment Research, "AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. " (11/16/2018)
Has AEterna Zentaris been receiving favorable news coverage?
News headlines about AEZS stock have trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AEterna Zentaris earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days.
Are investors shorting AEterna Zentaris?
AEterna Zentaris saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,039,407 shares, an increase of 62.1% from the December 31st total of 641,124 shares. Based on an average trading volume of 482,360 shares, the short-interest ratio is currently 2.2 days. Currently, 10.5% of the shares of the company are sold short. View AEterna Zentaris' Current Options Chain.
Who are some of AEterna Zentaris' key competitors?
Some companies that are related to AEterna Zentaris include Geron (GERN), TapImmune (MRKR), Aclaris Therapeutics (ACRS), Merus (MRUS), Axsome Therapeutics (AXSM), Synlogic (SYBX), MannKind (MNKD), Kamada (KMDA), Seres Therapeutics (MCRB), Savara (SVRA), Verastem (VSTM), Acer Therapeutics (ACER), Galectin Therapeutics (GALT), resTORbio (TORC) and Paratek Pharmaceuticals (PRTK).
What other stocks do shareholders of AEterna Zentaris own?
Who are AEterna Zentaris' key executives?
AEterna Zentaris' management team includes the folowing people:
- Mr. Michael V. Ward, Pres & CEO (Age 62)
- Ms. Leslie Auld, Sr. VP & CFO
- Mr. Brian Garrison, Sr. VP of Global Corp. Operations & Corp. Devel.
- Mr. Paul Burroughs, Director of Communications
- Dr. Nicola Ammer, Chief Medical Officer & VP of Clinical Devel.
Who are AEterna Zentaris' major shareholders?
AEterna Zentaris' stock is owned by many different of institutional and retail investors. Top institutional investors include Acadian Asset Management LLC (0.27%), O Shaughnessy Asset Management LLC (0.14%) and Jane Street Group LLC (0.06%).
Which major investors are buying AEterna Zentaris stock?
AEZS stock was acquired by a variety of institutional investors in the last quarter, including O Shaughnessy Asset Management LLC, Jane Street Group LLC and Acadian Asset Management LLC.
How do I buy shares of AEterna Zentaris?
Shares of AEZS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AEterna Zentaris' stock price today?
One share of AEZS stock can currently be purchased for approximately $4.13.
How big of a company is AEterna Zentaris?
AEterna Zentaris has a market capitalization of $67.90 million and generates $920,000.00 in revenue each year. The biopharmaceutical company earns $-16,790,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. AEterna Zentaris employs 34 workers across the globe.
What is AEterna Zentaris' official website?
How can I contact AEterna Zentaris?
AEterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company can be reached via phone at 843-900-3223 or via email at [email protected]
MarketBeat Community Rating for AEterna Zentaris (NASDAQ AEZS)
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe AEZS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEZS will underperform the S&P 500 over the long term. You may vote once every thirty days.
